Skip to content
TrialMatch
Sign up
Recruiting

Tau Networks in Psychotic Alzheimer's Disease

Create a profile to match View the full record on ClinicalTrials.gov

About this study

This research project aims to understand the brain mechanisms behind the manifestation of psychotic symptoms in Alzheimer´s disease (AD), and nature of the unique relationship with tau pathology. Amongst the cognitive manifestations of psychosis are impairments related to frontal circuits (social cognition, working memory and executive function deficits). The investigator's previous work suggests a role of tau pathology (one of the hallmarks of AD neuropathology) in the manifestation of psychosis in AD. However, the cerebral mechanisms that underly this association remain poorly understood. The overarching aim of the study is is to investigate the mechanisms by which tau network pathology may promote the presentation of psychosis in AD.

Condition
Alzheimer Disease, Alzheimer Disease With Delusions, Alzheimer Disease With Psychosis
Tested
[18F]-PI2620 PET scan
Sponsor
Northwell Health

Who can join

Age
65 to 85 years
Sex
All sexes
Healthy volunteers
Accepted

Inclusion 12

  • Minimum age: 65 years
  • Maximum age: 85 years
  • Study condition: Alzheimer Disease, Alzheimer Disease With Delusions, Alzheimer Disease With Psychosis
  • Age 65-85 years old.
  • Diagnosis of probable AD dementia according to National Institute on Aging-Alzheimer's Association (NIA-AA) criteria.
  • Mini-Mental State Examination (MMSE) score ≥ 10 and ≤ 26 at the screening visit.
  • Clinical Dementia Rating (CDR) score ≥ 0.5.
  • Logical Memory delay score of ≤8 for 16+ years of education, ≤4 for 8-15 years of education, and ≤2 for 0-7 years of education
  • No known genetic risk factors for dementia.
  • No cognitive complaint
  • Mini-Mental State Examination (MMSE) score ≥ 26 at the screening visit.
  • Logical Memory delay score of ≥9 for 16+ years of education, ≥5 for 8-15 years of education, and ≥3 for 0-7 years of education

Exclusion 15

  • Rosen-modified Hachinski Ischemia Score \> 4 at the screening visit.
  • History of stroke.
  • Evidence of a clinically relevant neurological disorder other than probable AD at the screening visit.
  • Participants with insulin dependent type 2 diabetes, a history of CVD, a history of epilepsy, a history of TBI with greater than 15 minutes of loss of consciousness, a movement disorder, autoimmune disease affecting the CNS, or delirium.
  • Evidence of a clinically relevant or unstable psychiatric disorder, based on DSM-5 criteria, including schizophrenia or other psychotic disorder, bipolar disorder, delirium, or current/active major depression.
  • History of alcoholism or drug dependency/abuse within the last 5 years before screening.
  • Presence of metal implants such as pacemakers, ear implants, internal bullet fragments or shrapnel.
  • Inability to lie flat for 1 hour approximately.
  • hearing impairment as evidenced by the inability to hear 500, 1000 and 6000 Hz bilaterally on an OAE evaluation. Subjects with hearing aides will be allowed to participate if they meet minimum hearing requirements.
  • Specific Inclusion Criteria for Alzheimer´s disease (AD) with Psychotic symptoms:
  • All the criteria for AD are met.
  • Presence of one (or more) of the following symptoms:
  • Visual or auditory hallucinations (e.g., seeing silent individuals standing in the room, seeing children in the yard, or seeing animals in the house).
  • Delusions (fixed false beliefs that the patient believes to be true, e.g., that the spouse is unfaithful, that possessions are being stolen, or that one is not who one claims to be).
  • \- Same criteria as AD participants above.

Where

1 site, 1 recruiting

The Feinstein Institutes for Medical Research

Manhasset, New York, United States

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.